This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

9 May 2012

Roche Abandons Dalcetrapib Trial

Disappointing phase-III trial results have led Roche to discontinue all dalcetrapib studies.

Roche has revealed that it is abandoning clinical development of its cardiovascular drug candidate dalcetrapib, following disappointing phase-III clinical trial results.


The dal-Outcomes trial aimed to assess the efficacy and safety of dalcetrapib alongside standard care in patients with stable coronary heart disease following an acute coronary syndrome.


However, Roche said that the independent Data and Safety Monitoring Board (DSMB) has recommended stopping the trial following the second interim analysis of results, which failed to show clinically meaningful efficacy.


As a result, the Swiss pharmaceutical group is terminating all studies in the dal-Heart programme.

Related News